-DOCSTART- -X- O
There -X- _ O
have -X- _ O
been -X- _ O
2040 -X- _ O
laboratory-confirmed -X- _ O
cases -X- _ O
of -X- _ O
Middle -X- _ B-Patient
East -X- _ I-Patient
respiratory -X- _ I-Patient
syndrome -X- _ I-Patient
coronavirus -X- _ I-Patient
( -X- _ I-Patient
MERS-CoV -X- _ I-Patient
) -X- _ I-Patient
in -X- _ O
27 -X- _ O
countries -X- _ O
, -X- _ O
with -X- _ O
a -X- _ O
mortality -X- _ O
rate -X- _ O
of -X- _ O
34.9 -X- _ O
% -X- _ O
. -X- _ O
There -X- _ O
is -X- _ O
no -X- _ O
specific -X- _ O
therapy. -X- _ O
The -X- _ O
current -X- _ O
therapies -X- _ O
have -X- _ O
mainly -X- _ O
been -X- _ O
adapted -X- _ O
from -X- _ O
severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS-CoV -X- _ O
) -X- _ O
treatments -X- _ O
, -X- _ O
including -X- _ O
broad-spectrum -X- _ B-Intervention
antibiotics -X- _ I-Intervention
, -X- _ I-Intervention
corticosteroids -X- _ I-Intervention
, -X- _ I-Intervention
interferons -X- _ I-Intervention
, -X- _ I-Intervention
ribavirin -X- _ I-Intervention
, -X- _ I-Intervention
lopinavir–ritonavir -X- _ I-Intervention
or -X- _ I-Intervention
mycophenolate -X- _ I-Intervention
mofetil -X- _ I-Intervention
, -X- _ O
and -X- _ O
have -X- _ O
not -X- _ O
been -X- _ O
subject -X- _ O
to -X- _ O
well- -X- _ O
organized -X- _ O
clinical -X- _ O
trials. -X- _ O
The -X- _ O
development -X- _ O
of -X- _ O
specific -X- _ O
therapies -X- _ O
and -X- _ O
vaccines -X- _ O
is -X- _ O
therefore -X- _ O
urgently -X- _ O
required. -X- _ O
We -X- _ O
examine -X- _ O
existing -X- _ O
and -X- _ O
potential -X- _ O
therapies -X- _ O
and -X- _ O
vaccines -X- _ O
from -X- _ O
a -X- _ O
molecular -X- _ O
perspective. -X- _ O
These -X- _ O
include -X- _ O
viral -X- _ O
S -X- _ O
protein -X- _ O
targeting -X- _ O
; -X- _ O
inhibitors -X- _ B-Intervention
of -X- _ I-Intervention
host -X- _ I-Intervention
proteases -X- _ I-Intervention
, -X- _ I-Intervention
including -X- _ I-Intervention
TMPRSS2 -X- _ I-Intervention
, -X- _ I-Intervention
cathepsin -X- _ I-Intervention
L -X- _ I-Intervention
and -X- _ I-Intervention
furin -X- _ I-Intervention
protease -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
of -X- _ I-Intervention
viral -X- _ I-Intervention
M -X- _ I-Intervention
( -X- _ I-Intervention
pro -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
the -X- _ I-Intervention
PL -X- _ I-Intervention
( -X- _ I-Intervention
pro -X- _ I-Intervention
) -X- _ I-Intervention
proteases -X- _ I-Intervention
; -X- _ I-Intervention
convalescent -X- _ I-Intervention
plasma -X- _ I-Intervention
; -X- _ I-Intervention
and -X- _ I-Intervention
vaccine -X- _ I-Intervention
candidates. -X- _ I-Intervention
The -X- _ O
Medline -X- _ O
database -X- _ O
was -X- _ O
searched -X- _ O
using -X- _ O
combinations -X- _ O
and -X- _ O
variations -X- _ O
of -X- _ O
terms -X- _ O
, -X- _ O
including -X- _ O
‘Middle -X- _ O
East -X- _ O
respiratory -X- _ O
syndrome -X- _ O
coronavirus’ -X- _ O
, -X- _ O
‘MERS-CoV’ -X- _ O
, -X- _ O
‘SARS’ -X- _ O
, -X- _ O
‘therapy’ -X- _ O
, -X- _ O
‘molecular’ -X- _ O
, -X- _ O
‘vaccine’ -X- _ O
, -X- _ O
‘prophylactic’ -X- _ O
, -X- _ O
‘S -X- _ O
protein’ -X- _ O
, -X- _ O
‘DPP4’ -X- _ O
, -X- _ O
‘heptad -X- _ O
repeat’ -X- _ O
, -X- _ O
‘protease’ -X- _ O
, -X- _ O
‘inhibitor’ -X- _ O
, -X- _ O
‘anti-viral’ -X- _ O
, -X- _ O
‘broad-spectrum’ -X- _ O
, -X- _ O
‘interferon’ -X- _ O
, -X- _ O
‘convalescent -X- _ O
plasma’ -X- _ O
, -X- _ O
‘lopinavir -X- _ O
ritonavir’ -X- _ O
, -X- _ O
‘antibodies’ -X- _ O
, -X- _ O
‘antiviral -X- _ O
peptides’ -X- _ O
and -X- _ O
‘live -X- _ O
attenuated -X- _ O
viruses’. -X- _ O
There -X- _ O
are -X- _ O
many -X- _ O
options -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
MERS-CoV-specific -X- _ O
therapies. -X- _ O
Currently -X- _ O
, -X- _ O
MERS-CoV -X- _ O
is -X- _ O
not -X- _ O
considered -X- _ O
to -X- _ O
have -X- _ O
pandemic -X- _ O
potential. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
high -X- _ O
mortality -X- _ O
rate -X- _ O
and -X- _ O
potential -X- _ O
for -X- _ O
mutations -X- _ O
that -X- _ O
could -X- _ O
increase -X- _ O
transmissibility -X- _ O
give -X- _ O
urgency -X- _ O
to -X- _ O
the -X- _ O
search -X- _ O
for -X- _ O
direct -X- _ O
, -X- _ O
effective -X- _ O
therapies. -X- _ O
Well-designed -X- _ O
and -X- _ O
controlled -X- _ O
clinical -X- _ O
trials -X- _ O
are -X- _ O
needed -X- _ O
, -X- _ O
both -X- _ O
for -X- _ O
existing -X- _ O
therapies -X- _ O
and -X- _ O
for -X- _ O
prospective -X- _ O
direct -X- _ O
therapies -X- _ O
. -X- _ O

